CAMBRIDGE, Mass., Sept. 3,
2024 /PRNewswire/ -- Akebia Therapeutics®,
Inc. (Nasdaq: AKBA), a biopharmaceutical company with the
purpose to better the lives of people impacted by kidney disease,
granted one newly-hired employee options to purchase an aggregate
of 4,000 shares of Akebia's common stock on August 30, 2024. The options were granted as an
inducement material to the employee entering into
employment with Akebia. The options were granted in accordance
with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $1.55 per share, which is equal to the closing
price of Akebia's common stock on the grant date. The stock options
vest over four years, with 25% of the shares vesting on the first
anniversary of the grant date and the remaining 75% of shares
vesting quarterly thereafter, in each case, subject to the new
employee's continued service with Akebia. Each stock option has a
10-year term and is subject to the terms and conditions of Akebia's
inducement award program and a stock option agreement covering the
grant.
About Akebia Therapeutics
Akebia Therapeutics,
Inc. is a fully integrated biopharmaceutical company with the
purpose to better the lives of people impacted by kidney
disease. Akebia was founded in 2007 and is
headquartered in Cambridge,
Massachusetts. For more information, please visit our
website at www.akebia.com, which does not form a
part of this release.
Akebia Therapeutics Contact
Mercedes
Carrasco
mcarrasco@akebia.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302237200.html
SOURCE Akebia Therapeutics, Inc.